The combination of lovastatin and chemotherapy is a promising therapeutic strategy for colon cancer.DNA damage induced by chemotherapeutic drugs could activate STING pathway. SHP2 inhibition in colon cancer cells reduces the activation of STING pathway.SHP2 agonist lovastatin impaired DNA repair via the dephosphorylation of PARP1 and therefore increased acumination of dsDNA and subsequently enhanced STING pathway-medicated anti-tumor immunity. The gene discussed is PARP1; the disease is colonic neoplasm.